The Oncology Institute appoints Kim Tzoumakas to Board of Directors

Oncology Institute, Inc.

Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.
She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.
She was not initially assigned to any board committees; term expires at 2027 annual meeting.

item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001553350-26-000007
form_type: 8-K
ticker: TOI
cik: 0001799191
company_name: Oncology Institute, Inc.
filed_at: 2026-02-23T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.213039+00:00
generated_at: 2026-05-16T01:13:59.187501+00:00
sec_items: ["5.02", "7.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.35
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001553350-26-000007
json_url: https://secwatch.observer/filing/0001553350-26-000007.json
markdown_url: https://secwatch.observer/filing/0001553350-26-000007.md
text_url: https://secwatch.observer/filing/0001553350-26-000007.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/0001553350-26-000007-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000007/toi_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001553350-26-000007

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.